Violet Therapeutics
Develops first-in-class small molecule therapies for neurodegenerative disease via glial cell signaling platform
$4.8MSeed+
Role not disclosedActivity from announced rounds
Develops first-in-class small molecule therapies for neurodegenerative disease via glial cell signaling platform